-
Use of empirical medical therapies for idiopathic male infertility in Australia and New Zealand Clin. Endocrinol. (IF 3.2) Pub Date : 2024-04-12 Sarah R. Catford, Darren Katz, Robert I. McLachlan
ObjectiveIdiopathic male infertility is common, yet there is no approved treatment. This study aimed to understand practice patterns towards empirical medical therapy (EMT) for idiopathic male infertility in Australia and New Zealand (NZ).DesignClinical members of the Endocrine Society of Australia, Fertility Society of Australia & NZ, and Urological Society of Australia & NZ were invited to complete
-
Diagnosis and management of urinary bladder paragangliomas: A Sino‐American‐European retrospective observational study Clin. Endocrinol. (IF 3.2) Pub Date : 2024-04-12 Yingxian Pang, Jing Zhang, Jingjing Jiang, Christina Pamporaki, Minghao Li, Nicole Bechmann, Leah Meuter, Yongbao Wei, Haijian Huang, Shenghui Huang, Xunbin Yu, Mercedes Robledo, Miguel J. Soria, Dewen Zhong, Shangyuan Xu, Henri J. L. M. Timmers, Johan F. Langenhuijsen, Xiaofeng Chen, Wanglong Deng, Timo Deutschbein, Hanna Remde, Long Wang, Hanyu Yao, Bin Yan, Annika M. A. Berends, Michiel N. Kerstens
ObjectiveParagangliomas of the urinary bladder (UBPGLs) are rare neuroendocrine tumours and pose a diagnostic and surgical challenge. It remains unclear what factors contribute to a timely presurgical diagnosis. The purpose of this study is to identify factors contributing to missing the diagnosis of UBPGLs before surgery.Design, Patients and MeasurementsA total of 73 patients from 11 centres in China
-
-
-
Endocrine, cardiac and neuropsychological aspects of adult congenital adrenal hyperplasia Clin. Endocrinol. (IF 3.2) Pub Date : 2024-04-04 Lukas Ochsner Ridder, Camilla Mains Balle, Anne Skakkebæk, Marie Lind‐Holst, Mette Mølby Nielsen, Pernille Hermann, Stinus Hansen, Dorte Guldbrand Nielsen, Sine Knorr, Niels Holmark Andersen, Mette Hansen Viuff, Agnethe Berglund, Claus Højbjerg Gravholt
ObjectiveTo investigate the metabolic, cardiovascular, and neuropsychological phenotype, quality of life (QoL), and hormonal regulation in individuals with congenital adrenal hyperplasia (CAH), a group of autosomal recessive disorders characterized by impaired synthesis of cortisol in the adrenal cortex and, if untreated compensatory hyperandrogenism. CAH is associated with an increased cardiovascular
-
Use of a dosimetry‐based RAI protocol for treatment of benign hyperthyroidism optimises response while minimising exposure to ionising radiation Clin. Endocrinol. (IF 3.2) Pub Date : 2024-04-03 Clare Miller, Amna Al‐Jabri, Liam O'Murchada, Mohamad Mustafa, Jennie Cooke, Niamh Phelan, Marie‐Louise Healy
BackgroundThe optimal treatment strategy for radioiodine (RAI) treatment protocols for benign hyperthyroidism remains elusive. Although individualised activities are recommended in European Law, many centres continue to provide fixed activities. Our institution implemented a dosimetry protocol in 2016 following years of fixed dosing which facilitates the calculation of individualised activities based
-
Expression of concern: ‘Metabolic response to selenium supplementation in women with polycystic ovary syndrome: A randomized, double‐blind, placebo‐controlled trial’ Clin. Endocrinol. (IF 3.2) Pub Date : 2024-04-01
‘This Expression of Concern is for the above article, published online on (16-December-2014) in Wiley Online Library https://doi.org/10.1111/cen.12699, and has been published by agreement between the journal's senior editors and Wiley Periodicals LLC. The expression of concern has been agreed due to concerns raised regarding the integrity of the research. An investigation has been conducted by The
-
Pseudoacromegaly—A challenging entity in the endocrine clinic: A systematic review Clin. Endocrinol. (IF 3.2) Pub Date : 2024-03-29 Pedro Marques, Inês Sapinho, Márta Korbonits
ObjectivePseudoacromegaly encompasses conditions with features of acromegaly/gigantism, but no growth hormone (GH) or insulin‐like growth factor‐1 (IGF‐1) excess. We aimed to review published pseudoacromegaly cases evaluated due to clinical suspicion of acromegaly.Design/PatientsPubMed/Medline search was conducted to identify reported pseudoacromegaly cases, which were systematically reviewed to ensure
-
Macroprolactin over time: Is there any point in rechecking it in people with a persistently elevated serum prolactin? Clin. Endocrinol. (IF 3.2) Pub Date : 2024-03-27 Mark Livingston, Syeda F. Hashmi, Sudarshan Ramachandran, Ian Laing, Adrian Heald
Macroprolactinemia may influence the interpretation of serum prolactin levels—a recognised phenomenon since 1981. The degree of macroprolactinaemia over time is less well described. We determined how macroprolactin status (based on polyethylene glycol (PEG) precipitation) varied by analysing serial measurements in hyperprolactinaemic individuals over a period of 9 years.
-
Service evaluation suggests variation in clinical care provision in adults with congenital adrenal hyperplasia in the UK and Ireland Clin. Endocrinol. (IF 3.2) Pub Date : 2024-03-17 Lauren Madden Doyle, S. Faisal Ahmed, Jessica Davis, Sue Elford, Yasir S. Elhassan, Lynette James, Neil Lawrence, Sofia Llahana, Grace Okoro, D. Aled Rees, Jeremy W. Tomlinson, Michael W. O'Reilly, Nils P. Krone
BackgroundCongenital adrenal hyperplasia (CAH) encompasses a rare group of autosomal recessive disorders, characterised by enzymatic defects in steroidogenesis. Heterogeneity in management practices has been observed internationally. The International Congenital Adrenal Hyperplasia registry (I‐CAH, https://sdmregistries.org/) was established to enable insights into CAH management and outcomes, yet
-
A nationwide registry‐based observational study of thyroid disease incidence in the Faroe Islands Clin. Endocrinol. (IF 3.2) Pub Date : 2024-03-14 Herborg Líggjasardóttir Johannesen, Anna Sofía Veyhe, Jens Andreassen, Pál Weihe, Marin Strøm, Guðrið Andorsdóttir, Aase Krogh Rasmussen, Ulla Feldt‐Rasmussen, Allan Carlé, Stig Andersen
ObjectiveThe occurrence of thyroid disease varies among populations. While the iodine nutrition level of the Faroese seems to have been decreasing over the past decades, there is no systematic evaluation of the thyroid disease pattern in the Faroe Islands. Such knowledge of thyroid disease occurrence in the North Atlantic region may support healthcare planning and prevention. To investigate incidence
-
Initial surgical management of sporadic medullary thyroid cancer: Guidelines based optimal care - A systematic review Clin. Endocrinol. (IF 3.2) Pub Date : 2024-03-12 Oded Cohen, Sharon Tzelnick, Gregory Randolph, Alessandra Rinaldo, Fernando Álvarez, Juan P. Rodrigo, Nabil F. Saba, Sandra Nuyts, June Corry, Antti A. Mäkitie, Vincent Vander Poorten, Cherie-Ann Nathan, Cesare Piazza, Alfio Ferlito
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor from parafollicular cells that produce calcitonin (Ct). Despite several existing guidelines for the surgical management of sporadic MTC (sMTC), optimal initial surgical management of the thyroid, the central and the lateral neck remains a matter of debate.
-
Response to letter to the editor: ‘Gonadal tumour screening in XY gonadal dysgenesis’ Clin. Endocrinol. (IF 3.2) Pub Date : 2024-03-12 Sabine E. Hannema, Katja P. Wolffenbuttel, Yolande van Bever, Hennie T. Bruggenwirth, Remko Hersmus, J. Wolter Oosterhuis, Leendert H. J. Looijenga
To the Editor, We read with interest the letter by Barbar et al. We recognise the clinical scenario described by Barbar et al. of patients with XY gonadal dysgenesis or other types of differences/disorders of sex development (DSD) with a significant risk of germ cell cancer who are hesitant to undergo a prophylactic gonadectomy.1 Whereas in children the situation is more complex, with parents having
-
Development and validation of a risk prediction model for preterm birth in women with gestational diabetes mellitus Clin. Endocrinol. (IF 3.2) Pub Date : 2024-03-11 Hanbing Li, Lingling Gao, Xiao Yang, Lu Chen
ObjectivesThis study aims to develop and validate a prediction model for preterm birth in women with gestational diabetes mellitus (GDM).DesignWe conducted a retrospective study on women with GDM who gave birth at the Third Affiliated Hospital of Sun Yat‐sen University, Guangzhou, China, between November 2017 and July 2021. We divided 1879 patients into a development set (n = 1346) and a validation
-
Use of thyroid hormones in hypothyroid and euthyroid patients: A survey of members of the Endocrine Society of Australia Clin. Endocrinol. (IF 3.2) Pub Date : 2024-03-11 Nicole Lafontaine, Suzanne J. Brown, Petros Perros, Enrico Papini, Endre V. Nagy, Roberto Attanasio, Laszlo Hegedüs, John P. Walsh
Hypothyroidism is a common endocrine condition usually managed with levothyroxine (LT4). However, controversy remains around the use of liothyronine (LT3). We aimed to investigate the practices of Australian endocrinologists when managing patients with hypothyroidism, their use of LT3 + LT4 combination therapy and use of thyroid hormones in euthyroid patients.
-
Beyond the bias! Sex distribution in paediatric growth hormone deficiency reexamined Clin. Endocrinol. (IF 3.2) Pub Date : 2024-03-11 Rohan K. Henry, Leena Mamilly, Monika Chaudhari, Brett G. Klamer, Melica Nikahd, Amy L. Pyle-Eilola
Various biases pertaining to stature account for a male sex predominance in growth hormone deficiency (GHD) cases diagnosed by endocrinology clinics. This manuscript will assess the sex distribution when biases are minimised.
-
-
-
Single and multi‐dose pharmacology of recombinant and urinary human chorionic gonadotrophin in men Clin. Endocrinol. (IF 3.2) Pub Date : 2024-03-06 David J. Handelsman, Amanda Idan, Reena Desai, Janelle Grainger, Catrin Goebel, Sue Sleiman, Sasha Savkovic, Dorothy Kouzios, Venna Jayadev, Ann J. Conway
ObjectiveHuman choriogonadotrophin (hCG) treatment of gonadotrophin‐deficient infertile men uses hCG of urinary (uhCG) or recombinant (rhCG) origin, but these treatments have not been compared nor are there studies defining rhCG dosing in men.DesignhCG products were studied in randomized cross‐over single‐dose studies of standard (Study 1, 1500 IU and 62.5 µg, respectively) or high (Study 2, 5000 IU
-
Does iodine fortification affect the risk of atrial fibrillation in incident hyperthyroidism? A national register-based cohort Clin. Endocrinol. (IF 3.2) Pub Date : 2024-03-04 Line T. Møllehave, Nils Knudsen, Eva Prescott, Inge B. Pedersen, Gitte Ravn-Haren, Allan Carlé, Allan Linneberg
Iodine fortification (IF) induces an initial increase followed by a decrease in the incidence of hyperthyroidism in the general population. Within the population of hyperthyroid patients, the sex-, age- and subtype distribution changes after IF. The risk of atrial fibrillation (AF) in hyperthyroid patients may be influenced by these factors. Therefore, we aimed to examine how the association between
-
Healthcare and research priorities for women with polycystic ovary syndrome in the UK National Health Service: A modified Delphi method Clin. Endocrinol. (IF 3.2) Pub Date : 2024-02-29 Bassel H. Al Wattar, Jhia Jiat Teh, Sophie Clarke, Ali Abbara, Rachel Morman, Alison Wilcox, Vikram Talaulikar
Polycystic ovary syndrome (PCOS) is a chronic lifelong condition affecting up to 20% of women worldwide. There is limited input from affected women to guide the provision of healthcare services and future research needs. Our objective was to scope the healthcare and research priorities of women with PCOS in the United Kingdom.
-
Expression of concern: ‘The effects of dietary approaches to stop hypertension diet on weight loss, anti‐Müllerian hormone and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial’ Clin. Endocrinol. (IF 3.2) Pub Date : 2024-02-27
‘This Expression of Concern is for the above article, published online on 18 March 2017 in Wiley Online Library https://doi.org/10.1111/cen.13333, and has been published by agreement between the journal's senior editors and Wiley Periodicals LLC. The expression of concern has been agreed due to concerns raised regarding the integrity of the research. An investigation has been conducted by The National
-
Reference limits for osteocalcin in infancy and early childhood: A longitudinal birth cohort study Clin. Endocrinol. (IF 3.2) Pub Date : 2024-02-22 Sara S. Berggren, Jovanna Dahlgren, Ola Andersson, Stefan Bergman, Josefine Roswall
The longitudinal variations in serum levels of the hormone osteocalcin is largely unknown during infancy and early childhood. Our aim was to establish reference limits for total serum osteocalcin during specific time points from birth until 5 years of age and present those in the context of sex, breastfeeding practices and gestational age (GA).
-
Evaluation of quality of life in children with precocious puberty Clin. Endocrinol. (IF 3.2) Pub Date : 2024-02-20 İlkay N. Yılmazer, Sema Nilay Abseyi, Gizem Şenyazar, Merih Berberoğlu, Zeynep Şıklar, Zehra Aycan
This study aimed to investigate the quality of life of patients with central precocious puberty (CPP) who required treatment and premature thelarche (PT) followed up without treatment and to compare the groups with and without treatment among themselves and with healthy children.
-
Hypoparathyroidism and mortality after total thyroidectomy: A nationwide matched cohort study Clin. Endocrinol. (IF 3.2) Pub Date : 2024-02-20 Rasmus Reinke, Sebastian Udholm, Christian Fynbo Christiansen, Martin Almquist, Stefano Londero, Lars Rejnmark, Thomas Bøjer Rasmussen, Lars Rolighed
Total thyroidectomy (TT) carries a risk of hypoparathyroidism (hypoPT). Recently, hypoPT has been associated with higher overall mortality rates. We aimed to evaluate the frequency of hypoPT and mortality in patients undergoing TT in Denmark covering 20 years.
-
Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial Clin. Endocrinol. (IF 3.2) Pub Date : 2024-02-18 Jun Mori, Yasuhisa Ohata, Yasuko Fujisawa, Yukihito Sato, Sebastian Röhrich, Michael Højby Rasmussen, Rikke Beck Bang, Reiko Horikawa
Somapacitan is a long-acting growth hormone (GH) derivative developed for the treatment of GH deficiency (GHD). This study evaluates the efficacy and tolerability of somapacitan in Japanese children with GHD after 104 weeks of treatment and after switch from daily GH.
-
Steroidogenic acute regulatory protein (STAR) deficiency: Our experience and systematic review for phenotype–genotype correlation Clin. Endocrinol. (IF 3.2) Pub Date : 2024-02-18 Aditya Phadte, Charushila Dhole, Samiksha Hegishte, Vijaya Sarathi, Anurag Lila, Jugal V. Gada, Saba Samad Memon, Sneha Arya, Manjiri Karlekar, Virendra Patil, Premlata K. Varthakavi, Nalini Shah, Nikhil M. Bhagwat, Tushar Bandgar
Lipoid congenital adrenal hyperplasia (LCAH) is caused by mutations in STAR. A systematic review of phenotype–genotype correlation and data on testicular histology in LCAH patients is unavailable. We aim to describe our experience and provide phenotype–genotype correlation.
-
Long-acting porcine ACTH stimulated salivary cortisol reduces the overdiagnosis of adrenal insufficiency compared to serum cortisol in cirrhosis liver Clin. Endocrinol. (IF 3.2) Pub Date : 2024-02-18 Vijayakumar Karthik, Puthiyaveetil Khadar Jabbar, Devadas Krishnadas, Abilash Nair, Geena Susan George, Chellamma Jayakumari, Sarayu Soumya, Arsha Asok, Shameer Basheer
There are no reliable methods in clinical practice to diagnose adrenal insufficiency (AI) in patients with cirrhosis owing to variable cortisol-binding protein levels. This leads to unreliable results in ACTH stimulated serum cortisol test. We aimed to estimate the long-acting porcine (LA)ACTH-stimulated serum and salivary cortisol levels of patients at different stages of cirrhosis using second generation
-
Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis Clin. Endocrinol. (IF 3.2) Pub Date : 2024-02-13 Jiayi Yu, Zheran Liu, Yonglin Su, Xingchen Peng, Yuping Xie
The poor overall prognosis of radioiodine refractory thyroid cancer is an inevitable challenge in managing this disease. A series of trials have demonstrated the antitumor activity of tyrosine kinase inhibitors (TKIs) in radioiodine refractory differentiated thyroid cancer (RAIR-DTC). However, the available evidence cannot determine the optimal choice of TKI in RAIR-DTC.
-
Natural history of ENPP1 deficiency: Nationwide Turkish Cohort Study of autosomal-recessive hypophosphataemic rickets type 2 Clin. Endocrinol. (IF 3.2) Pub Date : 2024-02-07 Fatma Dursun, İhsan Turan, Eda Çelebi Bitkin, Elvan Bayramoğlu, Atilla Çayır, Şenay Savaş Erdeve, Esra Deniz Papatya Çakır, Emine Çamtosun, Semine Ozdemir Dilek, Heves Kırmızıbekmez, Metin Eser, Ayberk Türkyılmaz, Gülay Karagüzel
Autosomal-recessive hypophosphataemic rickets type 2 (ARHR2) is a rare disease that is reported in survivors of generalized arterial calcification of infancy (GACI).
-
The diagnostic performance of copeptin in clinical practice: A prospective study Clin. Endocrinol. (IF 3.2) Pub Date : 2024-01-30 Penelope Trimpou, Ioannis Bounias, Olof Ehn, Ola Hammarsten, Oskar Ragnarsson
Plasma copeptin is a relatively new biomarker for evaluation of arginine vasopressin (AVP) secretion. The aim of this study was to test the diagnostic performance of copeptin in patients with polyuria-polydipsia syndrome.
-
Peak serum luteinising hormone cut-off during gonadotropin-releasing hormone analogue test for diagnosing central precocious puberty was lower in girls with obesity as compared with girls with normal weight Clin. Endocrinol. (IF 3.2) Pub Date : 2024-02-01 Natee Sakornyutthadej, Pat Mahachoklertwattana, Somboon Wankanit, Preamrudee Poomthavorn
Serum luteinising hormone (LH) concentration has been reported to be lower in girls with overweight and obesity (OW/OB) as compared with girls with normal weight (NW). This study aimed to evaluate peak serum LH concentration during gonadotropin-releasing hormone analogue (GnRHa) test in girls with OW/OB and NW who had central precocious puberty (CPP) and to determine peak serum LH cut-off for diagnosing
-
Gonadal tumour screening in XY gonadal dysgenesis Clin. Endocrinol. (IF 3.2) Pub Date : 2024-01-27 Bruna Barbar, Neomal De Silva, Timothy Cheetham, Claire Wood, Richard Quinton
We read with great interest the recent paper by Hannema et al.1 that we found particularly illuminating in respect of our patient with 46XY gonadal dysgenesis, who continues to decline prophylactic gonadectomy. Disorders of sex development (DSD) are a group of rare disorders involving abnormalities in karyotype, steroidogenesis, androgen action or gonadal development, resulting in various phenotypic
-
Point-of-care ultrasound is a useful adjunct tool to a clinician's assessment in the evaluation of severe hyponatraemia Clin. Endocrinol. (IF 3.2) Pub Date : 2024-01-16 Latif R. Rahman, Eka Melson, Salam Al Alousi, Muhammad Sardar, Miles J. Levy, Shahriar Shafiq, Faizanur Rahman, Tim Coats, Narendra L. Reddy
Hyponatraemia is the most common electrolyte disorder in inpatients resulting mainly from an imbalance in water homeostasis. Intravascular fluid status assessment is pivotal but is often challenging given multimorbidity, polypharmacy and diuretics use. We evaluated the utility of point-of-care ultrasound (POCUS) as an adjunct tool to standard practice for fluid assessment in severe hyponatraemia patients
-
Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19 Clin. Endocrinol. (IF 3.2) Pub Date : 2024-01-17 Kerri Devine, Clark D. Russell, Giovanny R. Blanco, Brian R. Walker, Natalie Z. M. Homer, Scott G. Denham, Joanna P. Simpson, Olivia C. Leavy, Omer Elneima, Hamish J. C. McAuley, Aarti Shikotra, Amisha Singapuri, Marco Sereno, Ruth M. Saunders, Victoria C. Harris, Linzy Houchen-Wolloff, Neil J. Greening, Nazir I. Lone, Mathew Thorpe, William Greenhalf, James D. Chalmers, Ling-Pei Ho, Alex Horsley,
Endocrine systems are disrupted in acute illness, and symptoms reported following coronavirus disease 2019 (COVID-19) are similar to those found with clinical hormone deficiencies. We hypothesised that people with severe acute COVID-19 and with post-COVID symptoms have glucocorticoid and sex hormone deficiencies.
-
Characteristics of bone mineral density in patients with functional hypothalamic amenorrhoea and its association with reproductive hormones and body composition Clin. Endocrinol. (IF 3.2) Pub Date : 2024-01-16 Ye Lu, Ping Lu, Lixian Lin, Hang Chen, Feifei Zhang, Xin Li
Bone mineral density (BMD) is typically reduced in patients with female athlete triad (FAT) and anorexia nervosa (AN). However, bone health in most patients with functional hypothalamic amenorrhoea (FHA), who may not suffer from severe energy deficiency, has not received adequate attention in clinical practice. This study aimed to investigate BMD and its association with clinical and endocrine features
-
Assessment of plasma dexamethasone levels after 1-mg dexamethasone suppression test in adults with obesity Clin. Endocrinol. (IF 3.2) Pub Date : 2024-01-16 Pimonrat Paopongpaiboon, Prangareeya Santisitthanon, Natnicha Houngngam, Thiti Snabboon, Patchaya Boonchaya-anant
The 1-mg overnight dexamethasone suppression test is the most frequently used screening test for Cushing's syndrome. It has been proposed that people with obesity may have insufficient plasma dexamethasone levels for the test which may result in false positives. We sought to compare the plasma dexamethasone levels after 1-mg dexamethasone suppression test in healthy obese participants and in optimal-weight
-
The causal relationship between autoimmune thyroid disorders and telomere length: A Mendelian randomization and colocalization study Clin. Endocrinol. (IF 3.2) Pub Date : 2024-01-12 Xue Liu, Jie Yuan, Shuai Liu, Xinhui Wang, Mulin Tang, Xue Meng, Yuchen Li, Yuwei Chai, Yuyao Wang, Guoyu Tian, Xueying Liu, Huizhi Zhou, Chunjia Kou, Li Zhang, Zhongshang Yuan, Haiqing Zhang
This study aimed to evaluate whether there is a causal relationship between autoimmune thyroid disorders (AITDs) and telomere length (TL) in the European population and whether there is reverse causality. In this study, Mendelian randomization (MR) and colocalization analysis were conducted to assess the potential causal relationship between AITDs and TL using summary statistics from large-scale genome-wide
-
Risk assessment for aortic dissection in Turner syndrome: The role of the aortic growth rate Clin. Endocrinol. (IF 3.2) Pub Date : 2024-01-12 Matilde Calanchini, James Bradley-Watson, Fiona McMillan, Saul Myerson, Andrea Fabbri, Helen E. Turner, Elizabeth Orchard
The risk of aortic dissection (AoD) is increased in Turner syndrome (TS) but predicting those at risk is difficult. Based on scarce evidence, preventive aortic surgery is recommended when aortic diameter increases >5 mm/year. To investigate the aortic growth rate in TS and TS-related conditions associated with aortic growth. We also reported our experience of women who suffered aortic dissection (AoD)
-
Paediatric perspectives in the diagnosis of polyuria-polydipsia syndrome Clin. Endocrinol. (IF 3.2) Pub Date : 2024-01-02 Tony Huynh, Dana Signal, Mirjam Christ-Crain
The elucidation of the underlying cause of polyuria-polydipsia syndrome (PPS) is a challenging—especially in the differentiation of partial defects of arginine vasopressin (AVP) secretion or action from primary polydipsia. The water deprivation test has been utilized for many decades, and its application in the paediatric population has been applied using parameters predominantly established in adult
-
IRS1 promotes thyroid cancer metastasis through EMT and PI3K/AKT pathways Clin. Endocrinol. (IF 3.2) Pub Date : 2024-01-03 Fang Yu, Dongdong Huang, Yeye Kuang, Jian Dong, Qingmei Han, Jie Zhou, Xiaodong Teng
Insulin receptor substract 1 (IRS1) protein is an important signal transduction adapter for extracellular signal transduction from insulin-like growth factor-1 receptor and its family members to IRS1 downstream proteins. IRS1 has been reported to be involved in tumourigenesis and metastasis in some of solid tumors. Investigating the role of IRS1 in thyroid cancer can help to screen high risk patients
-
Effect of mild cortisol cosecretion on body composition and metabolic parameters in patients with primary hyperaldosteronism Clin. Endocrinol. (IF 3.2) Pub Date : 2024-01-01 Nabeel Mansour, Denise Bruedgam, Ulrich Dischinger, Lydia Kürzinger, Christian Adolf, Roman Walter, Osman Öcal, Vanessa F. Schmidt, Jan Rudolph, Jens Ricke, Nicole Reisch, Martin Reincke, Moritz Wildgruber, Daniel Heinrich
To investigate the effects of simultaneous cortisol cosecretion (CCS) on body composition in computed tomography (CT)-imaging and metabolic parameters in patients with primary aldosteronism (PA) with the objective of facilitating early detection.
-
Anaemia-based screening for resistance to thyroid hormone alpha in children Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-26 Gözde Akın Kağızmanlı, Özgür Kırbıyık, Ayhan Abacı, Ece Böber, Uluç Yiş, Korcan Demir
The hypothyroid phenotype associated with resistance to thyroid hormone alpha (RTH-α) is associated with a diverse clinical picture. On the other hand, thyroid-stimulating hormone (TSH) levels are normal. Free triiodothyronine (fT3) and free thyroxine (fT4) levels can also be normal; however, normo- or macrocytic anaemia is usually present in reported cases. Diagnosis is challenging and there is limited
-
Lower creatinine to cystatin C ratio is associated with an increased risk of MASLD: A cross-sectional and prospective study of 368,634 UK Biobank participants Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-26 Jiaren Wang, Lin Zeng, Chang Hong, Hao Cui, Weizhen Wang, Hongbo Zhu, Qimei Li, Yan Li, Ruining Li, Jingzhe He, Hong Zhu, Li Liu, Lushan Xiao
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects many populations, and screening out the high-risk populations at an early stage is a challenge. As a sarcopenia index, the relationship between creatinine to cystatin C ratio (CCR) and MASLD remains unclear. This cross-sectional, prospective study aimed to explore the relationship between CCR and MASLD. Design Firstly, explored
-
Rare forms of congenital adrenal hyperplasia Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-21 Busra Gurpinar Tosun, Tulay Guran
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders due to pathogenic variants in genes encoding enzymes and cofactors involved in adrenal steroidogenesis. Although 21-hydroxylase, 11β-hydroxylase, 3β-hydroxysteroid dehydrogenase type 2, 17α-hydroxylase/17,20-lyase, P450 oxidoreductase, steroidogenic acute regulatory protein, cholesterol side-chain cleavage enzyme deficiencies
-
Potassium levels in women with polycystic ovary syndrome using spironolactone for long-term Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-21 Thais A. deOliveira, Lucas B. Marchesan, Poli M. Spritzer
Spironolactone (SPL) has been used to manage hyperandrogenic manifestations in women with polycystic ovary syndrome (PCOS), but data on the risk of hyperkalemia in this population are scarce. The aim of this study was to evaluate the incidence of hyperkalemia in women with PCOS using SPL in the long term.
-
High prevalence of severe sleep cycle disruption in de novo acromegaly and underdiagnosis by common clinical screening tools: A prospective, observational, cross-sectional study Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-21 Andrew S. Powlson, Anand K. Annamalai, Samantha Moir, Alison J. Webb, Laksha Bala, Johann Graggaber, Narayanan Kandasamy, Olympia Koulouri, David J. Halsall, John M. Shneerson, Mark Gurnell
Although sleep disordered breathing (SDB) is well-recognised in acromegaly, most studies have reported heterogeneous, often heavily treated, groups and few have performed detailed sleep phenotyping at presentation.
-
Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-21 Jimmy Ho Cheung Mak, David Tak-Wai Lui, Carol Ho-Yi Fong, Chloe Yu-Yan Cheung, Ying Wong, Alan Chun-Hong Lee, Ruby Lai-Chong Hoo, Aimin Xu, Kathryn Choon-Beng Tan, Karen Siu-Ling Lam, Chi-Ho Lee
Baseline circulating thrombospondin-2 (TSP2) level was identified as a potential novel hepatic fibrosis biomarker that associates with development and progression of hepatic fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes. Here, we investigated whether circulating TSP2 levels changed with improvement in liver stiffness (LS), which reflects liver fibrosis on transient
-
Working towards convergence of the clinical management of differences of sex development/intersex conditions and the human rights framework: A case study Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-07 Martine Cools, Emmanuelle Verhagen, Piet Hoebeke, Eline Van Hoecke, Pieter Cannoot
Medical treatments that aim to modify the appearance of the genitals in children who are born with a difference of sex development/intersex (DSD/I*) condition are highly controversial. Human Rights bodies worldwide have argued that such treatments are conflicting with the child's right of personal autonomy and should be legally restricted to the unique situation where the child's physical health is
-
Low-dose diazoxide therapy in hyperinsulinaemic hypoglycaemia Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-07 Amy Yi-Lin Ng, Pankaj Agrawal, Roopa Vijayan, Ved B. Arya, Ritika R. Kapoor, Pratik Shah
Dear Editor, Hyperinsulinaemic hypoglycaemia (HH) is a rare condition with elevated and unregulated levels of insulin, resulting in low blood glucose concentrations. It is the most common cause of persistent hypoglycaemia in infants and children, causing a high risk of developing brain injuries such as epilepsy, cerebral palsy, or neurological impairment.1 Diazoxide remains the first-line medication
-
Changes in thyroid function and evolution of subclinical thyroid disease in older men Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-07 Stephanie Y. Tan, S. A. Paul Chubb, Leon Flicker, Osvaldo P. Almeida, Jonathan Golledge, Graeme J. Hankey, Bu B. Yeap
Prevalence of subclinical thyroid disease increases with age, but optimal detection and surveillance strategies remain unclear particularly for older men. We aimed to assess thyroid stimulating hormone (TSH) and free thyroxine (FT4) concentrations and their longitudinal changes, to determine the prevalence and incidence of subclinical thyroid dysfunction in older men.
-
Commentary on studies investigating low-dose diazoxide in hyperinsulinism Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-07 Tony Huynh
Diazoxide, utilised in hyperinsulinism since the 1960s,1 is the recommended first-line pharmacological therapy for children with hyperinsulinism.2 It blocks the sulfonylurea receptor 1 (SUR1) subunit of KATP-channel on pancreatic beta cells, increasing the permeability to potassium ions leading to hyperpolarization of the cells and inhibition of calcium-dependent insulin secretion.3 The recently published
-
Low-dose diazoxide is safe and effective in infants with transient hyperinsulinism Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-07 Neha Malhotra, Daphne Yau, Annaruby Cunjamalay, Buddhi Gunasekara, Athanasakopoulou S., Clare Gilbert, Kate Morgan, Mehul Dattani, Antonia Dastamani
Transient hyperinsulinism (THI) is the most common form of recurrent hypoglycaemia in neonates beyond the first week of life. Although self-resolving, treatment can be required. Consensus guidelines recommend the lower end of the diazoxide 5–15 mg/kg/day range in THI to reduce the risk of adverse events. We sought to determine if doses <5 mg/kg/day of diazoxide can be effective in THI.
-
Levothyroxine for a high-normal TSH in unexplained infertility Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-05 Francesca Galbiati, Tahereh Orouji Jokar, Lars M. Howell, Runjia Li, Lindsay T. Fourman, Hang Lee, Jong-Hyeon Jeong, Pouneh K. Fazeli
Unexplained infertility affects nearly one-third of infertile couples. Women with unexplained infertility are more likely to have a high-normal thyroid-stimulating hormone level (TSH: 2.5–5 mIU/L) compared to women with severe male factor infertility. Practice guidelines vary on whether treatment should be initiated for TSH levels >2.5 mIU/L in women attempting conception because the effects of treating
-
Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma —A systematic review and meta-analysis Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-04 Kunal Ramesh Chandekar, Swayamjeet Satapathy, Chandrasekhar Bal
The utility of radioiodine (RAI) therapy in intermediate-risk papillary thyroid carcinoma (PTC) remains a topic of ongoing discussion. This systematic review and meta-analysis aimed to consolidate existing evidence on the impact of postoperative RAI therapy on recurrence and survival outcomes in intermediate-risk PTC.
-
IGF-1 as screening tool for acromegaly and adult-onset growth hormone deficiency in the Netherlands Clin. Endocrinol. (IF 3.2) Pub Date : 2023-12-04 Mark R. Postma, André P. van Beek, Melanie M. van der Klauw, Eef G. W. M. Lentjes, Anneke C. Muller Kobold
Insulin-like growth factor 1 (IGF-1) measurements play a central role in the diagnosis and follow-up of acromegaly and growth hormone deficiency. However, improving health care outcomes for these patients involves an intricate process of laboratory diagnostics and skilled health care professionals. The integrated effects of IGF-1 reports on diagnosis and treatment decisions are yet unknown.
-
Adequacy of thyroid hormone replacement for people with hypothyroidism in real-world settings: A systematic review and meta-analysis of observational studies Clin. Endocrinol. (IF 3.2) Pub Date : 2023-11-30 Agathoklis Efthymiadis, Matthew Henry, Dimitrios Spinos, Marianthi Bourlaki, Alexandros Tsikopoulos, Angeliki Bourazana, Anastasios Bastounis, Konstantinos Tsikopoulos
Thyroid hormone under-replacement and over-replacement are associated with adverse health outcomes. This systematic review aimed to evaluate the extent of thyroid hormone replacement adequacy for patients with known hypothyroidism in real-word settings, excluding those receiving thyroid hormone suppressive therapy as thyroid cancer treatment.
-
The use of prednisolone during Ramadan fasting in patients with adrenal insufficiency Clin. Endocrinol. (IF 3.2) Pub Date : 2023-11-29 Nicholas Ken Yoong Hee, Quan Hziung Lim, Sharmila Paramasivam, Lee Ling Lim, Shireene Vethakkan, Shubash Shander Ganapathy, Jeyakantha Ratnasingam
Once daily prednisolone taken at predawn has been proposed to be the glucocorticoid replacement of choice in patients with adrenal insufficiency (AI) who intend to fast for the month of Ramadan. However, the effects of prednisolone on metabolic parameters and quality of life during fasting for Ramadan are unknown.
-
Lymph node imaging for thyroid cancer Clin. Endocrinol. (IF 3.2) Pub Date : 2023-11-27 Simon A. Holoubek, Rebecca S. Sippel
Cervical lymph nodes (LNs) in the central (level VI) and lateral (levels II–V) compartments of the neck are the most common sites of locoregional metastases associated with thyroid cancer. Prophylactic nodal dissections are uncommon in modern thyroid surgery and are not routinely performed due to concern for increased morbidity and do not offer improved survival. Therefore, a selective approach for
-
Systematic review of guidelines on neonatal hypoglycemia Clin. Endocrinol. (IF 3.2) Pub Date : 2023-11-24 Keren Luo, Jun Tang, Meng Zhang, Yang He
In recent years, a series of clinical guidelines on neonatal hypoglycemia have been developed in different countries and regions. This systematic review was aimed at providing evidence for clinical decision-making and providing ideas for future research by comparatively analyzing the contents of various guidelines.